Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2025
Event: Entry into a Material Definitive Agreement (Oxford Loan Agreement) and issuance of unregistered equity securities (Warrants).
Key Financial Metrics and Transaction Details
This filing details a new debt facility rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction terms include:
- Total Facility Size: Up to $150.0 million.
- Initial Funding: $100.0 million funded on the Closing Date.
- Remaining Availability: $50.0 million available at the Lenders' sole discretion upon Company request.
- Interest Rate: 5.61% plus the greater of (i) 1-Month Term SOFR or (ii) 4.34%.
- Repayment Schedule: Interest-only payments through February 1, 2028. Principal payments begin March 1, 2028, over 23 months.
- Maturity Date: January 1, 2030.
- Final Payment: 9.0% of total repaid principal due to Lenders upon maturity, acceleration, or prepayment.
- Prepayment Penalty: Ranges from 2.0% to 5.0% depending on timing.
- Collateral: First priority perfected lien on substantially all present and future assets.
Material Changes and Equity Issuance
The Company entered into a significant new debt obligation and issued equity-linked securities:
- Term A Warrants: Issued 140,741 warrants to purchase Common Stock at an exercise price of $14.21 per share in connection with the initial $100.0 million tranche.
- Term B Warrants: If the remaining $50.0 million is funded, additional warrants will be issued equal to 2.0% of the additional funding amount. The exercise price will be the lower of the 10-day average closing price or the closing price immediately preceding the funding.
- Warrant Terms: Immediately exercisable with a 10-year expiration period.
- Covenants: The agreement includes restrictions on incurring additional debt, granting liens, mergers, investments, affiliate transactions, dividends, and asset sales. It also mandates a minimum liquidity threshold.
Guidance, Risks, and Contingencies
Management Commentary: The transaction is intended to provide financial capacity and strategic flexibility for the Company's therapeutic candidates and clinical development.
Risks and Contingencies:
- Events of Default: Include non-payment, covenant violations, material adverse changes, cross-defaults, bankruptcy, and delisting.
- Consequences of Default: Lenders may declare all obligations immediately due and payable and proceed against collateral.
- Forward-Looking Statements: The Company cautions that actual results may differ due to risks regarding clinical trial progress, regulatory approvals, commercialization, and the ability to raise additional funds.
- Liquidity Requirement: The Company must maintain a minimum liquidity threshold, which may increase based on pipeline development changes.
Investor Verification Checklist
- Verify the Company's current cash position and whether the $100.0 million funding has been received.
- Review the specific "minimum liquidity threshold" covenant to understand future cash flow constraints.
- Assess the dilution impact of the 140,741 Term A Warrants and potential Term B Warrants.
- Confirm the Company's ability to meet the interest-only payments until 2028 and principal payments thereafter.
- Examine the "Material Adverse Change" definition in the loan agreement for potential triggers related to clinical trial outcomes.